Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Fay Kastrinos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2518-0100; OpenAlex author ID A5034561048. Sources: ClinicalTrials.gov.

Their work

Papers
29 (first author 2, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
149
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 3 papers · 2021: 7 papers · 2022: 5 papers · 2023: 2 papers · 2024: 4 papers · 2025: 2 papers · 2026: 4 papers

Papers 29

  1. Hereditary Pancreatic Cancer. Last author DOI 10.1016/j.gtc.2026.07.002↗
  2. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.08.034↗
  3. The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective S… Co-author DOI 10.3390/jcm15197355↗
  4. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  5. Identification of patients at risk for pancreatic cancer in a 3-year timeframe based on machine learning algorithms. Co-author DOI 10.1038/s41598-025-89607-8↗
  6. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  7. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  8. The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Co-author DOI 10.1002/cncr.35383↗
  9. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  10. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  11. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
  12. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  13. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Co-author DOI 10.1002/cnr2.1565↗
  14. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  15. Familial Predisposition and Genetic Risk Factors Associated with Pancreatic Cancer. Last author DOI 10.1016/j.giec.2021.09.001↗
  16. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  17. Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Co-author DOI 10.1053/j.gastro.2021.11.021↗
  18. COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Co-author DOI 10.1016/j.pan.2021.04.005↗
  19. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
  20. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  21. Inherited predisposition to pancreatic cancer. Last author DOI 10.1053/j.seminoncol.2021.02.006↗
  22. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001835↗
  23. Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—Letter Co-author DOI 10.1158/1940-6207.capr-21-0233↗
  24. How I Approach Screening for Pancreatic Cancer First author DOI 10.14309/ajg.0000000000001305↗
  25. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, upda… Co-author DOI 10.1007/s00261-019-02290-y↗
  26. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  27. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  28. Screening for Pancreatic Cancer First author DOI 10.1001/jama.2019.9690↗
  29. Surveillance for pancreatic cancer in high-risk individuals. Co-author DOI 10.1002/bjs5.50180↗

Trials 1

  1. Pancreatic Cancer Genetics Principal investigator NCT01102569↗

Closest collaborators

The 25 strongest of 149 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Randall E. Brand · 13 shared papers, 2019–2026 · strength 1.74
  2. Diane M. Simeone · 8 shared papers, 2020–2026 · strength 1.13
  3. Aimee Lee Lucas · 9 shared papers, 2019–2026 · strength 1.09
  4. Bryson W. Katona · 8 shared papers, 2021–2026 · strength 1.06
  5. Salvatore Paiella · 7 shared papers, 2019–2026 · strength 1.00
  6. Elena M. Stoffel · 9 shared papers, 2019–2024 · strength 0.98
  7. Sonia S. Kupfer · 6 shared papers, 2021–2026 · strength 0.97
  8. Kimberly J. Hilfrank · 3 shared papers, 2021–2026 · strength 0.91
  9. Sheila D. Rustgi · 3 shared papers, 2021–2026 · strength 0.91
  10. James J. Farrell · 7 shared papers, 2020–2024 · strength 0.88
  11. Marcia Irene Canto · 8 shared papers, 2019–2024 · strength 0.84
  12. Michael Goggins · 8 shared papers, 2019–2024 · strength 0.84
  13. Sapna Syngal · 7 shared papers, 2019–2024 · strength 0.73
  14. Jessica N. Everett · 5 shared papers, 2021–2026 · strength 0.71
  15. Rosalie C. Sears · 4 shared papers, 2021–2026 · strength 0.70
  16. Walter Gwang-Up Park · 4 shared papers, 2020–2026 · strength 0.65
  17. Elana Levinson · 2 shared papers, 2024–2026 · strength 0.58
  18. George Zogopoulos · 4 shared papers, 2021–2026 · strength 0.56
  19. Norma Alonzo Palma · 2 shared papers, 2026 · strength 0.49
  20. Lisa A. Ford · 2 shared papers, 2026 · strength 0.49
  21. Thomas Charles King · 2 shared papers, 2026 · strength 0.49
  22. Erkut Hasan Borazanci · 2 shared papers, 2026 · strength 0.49
  23. Raymond Couric Wadlow · 3 shared papers, 2023–2026 · strength 0.48
  24. Anil K. Rustgi · 4 shared papers, 2020–2024 · strength 0.46
  25. Ralph H. Hruban · 4 shared papers, 2019–2024 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.